Podcast Episodes

Back to Search
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics

The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more …

2 years, 6 months ago

Short Long
View Episode
The top life sciences startups to watch this year
The top life sciences startups to watch this year

Welcome to 2024! This week we're discussing BioSpace's tenth annual list of the hottest new life sciences companies in the U.S. NextGen Class of 2024…

2 years, 6 months ago

Short Long
View Episode
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital

How can startup leaders support long-term sustainable growth and investment?

BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke…

2 years, 6 months ago

Short Long
View Episode
Every move you make: Biopharma industry under heavy scrutiny
Every move you make: Biopharma industry under heavy scrutiny

Biden administration flexes regulatory muscles, putting pressure on the biopharma industry over ‘price gouging’ and invoking march-in rights; meanwhi…

2 years, 6 months ago

Short Long
View Episode
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital

What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding out…

2 years, 6 months ago

Short Long
View Episode
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny

That was Week with a capital W. Two major FDA approvals for sickle cell came through on Friday - Casgevy, the first-ever CRISPR-based gene editing th…

2 years, 6 months ago

Short Long
View Episode
Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA
Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA

This is the second part of our discussion on the evolution of artificial intelligence and its impact on life sciences with guests from Microsoft and …

2 years, 6 months ago

Short Long
View Episode
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA

Over the last year, the reaction to generative AI has changed - and so have behaviors. People are integrating AI to become more productive and it is …

2 years, 7 months ago

Short Long
View Episode
GLP-1 and ADC rollercoasters pick up speed
GLP-1 and ADC rollercoasters pick up speed

The weight loss market sees more ups and downs - Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medic…

2 years, 7 months ago

Short Long
View Episode
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior

Patient behavior has always had an influence on clinical trials - so how do we contend with missing and/or irregular data now that it is feeding AI m…

2 years, 7 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us